Screener
Veracyte VCYT Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized, 79,791,856 and 79,359,005 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 80 | 79 |
| Additional paid-in capital | 1,701,470 | 1,695,339 |
| Accumulated deficit | (348,923) | (377,630) |
| Accumulated other comprehensive loss | (8,221) | (8,212) |
| Total stockholders’ equity | 1,344,406 | 1,309,576 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's common stock, par value (in dollars per share)?
- Veracyte (VCYT) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Veracyte's common stock, par value (in dollars per share) changed year-over-year?
- Veracyte's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Veracyte's common stock, par value (in dollars per share)?
- Over 5 years (2020 to 2025), Veracyte's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
Ask your AI about Veracyte's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude